Cargando…

A case report of metastatic giant sarcomatoid melanoma with BRAF V600E mutation: a complete response to targeted therapy

Sarcomatoid melanoma is an extremely rare pattern of malignant melanoma, and only few cases have been described throughout the literature. We herein report a case of a patient with newly diagnosed, metastatic giant sarcomatoid melanoma of the arm. The patient underwent surgical removal of the huge m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Torresetti, Matteo, Brancorsini, Donatella, Morgese, Francesca, Cognigni, Valeria, Scalise, Alessandro, Berardi, Rossana, Di Benedetto, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456614/ https://www.ncbi.nlm.nih.gov/pubmed/32922664 http://dx.doi.org/10.18632/oncotarget.27701

Ejemplares similares

Potential benefit of β-glucans as adjuvant therapy in immuno-oncology: a review
por: Cognigni, Valeria, et al.
Publicado: (2021)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

Versatility of the O-Z flap for back reconstruction after giant basal cell carcinoma resection: A case report and review of the literature
por: Torresetti, Matteo, et al.
Publicado: (2019)

BRaf(V600E) cooperates with Pten silencing to elicit metastatic melanoma
por: Dankort, David, et al.
Publicado: (2009)

Impact of phosphoinositide-3-kinase and vitamin D3 nuclear receptor single-nucleotide polymorphisms on the outcome of malignant melanoma patients
por: Morgese, Francesca, et al.
Publicado: (2017)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

A peculiar case of large primary cutaneous Ewing’s sarcoma of the foot: Case report and review of the literature
por: Grassetti, Luca, et al.
Publicado: (2015)

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
por: Sponghini, Andrea P, et al.
Publicado: (2015)

Frequency of BRAF V600E Mutation in the Mexican Population of Patients With Metastatic Melanoma
por: Ruiz-Garcia, Erika, et al.
Publicado: (2017)

Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations
por: Giunta, Emilio Francesco, et al.
Publicado: (2020)

The Role of Surgical Drainage on Complications after Sentinel Lymph Node Biopsy for Melanoma
por: Torresetti, Matteo, et al.
Publicado: (2022)

Long Term Survival and Continued Complete Response of Vemurafenib in a Metastatic Melanoma Patient with BRAF V600K Mutation
por: Sahadudheen, K., et al.
Publicado: (2016)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
por: Al Hashmi, Muna, et al.
Publicado: (2020)

Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival
por: Ito, Takamichi, et al.
Publicado: (2020)

Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success?
por: Sigalotti, L, et al.
Publicado: (2011)

Intra- and Inter-Tumor Heterogeneity of BRAF(V600E)Mutations in Primary and Metastatic Melanoma
por: Yancovitz, Molly, et al.
Publicado: (2012)

Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib
por: Nowara, Elzbieta, et al.
Publicado: (2016)

Plasma proteome alterations by MAPK inhibitors in BRAF(V600)-mutated metastatic cutaneous melanoma()()
por: Babačić, Haris, et al.
Publicado: (2021)

BRAF V600-Mutated Metastatic Melanoma and Targeted Therapy Resistance: An Update of the Current Knowledge
por: Florent, Laetitia, et al.
Publicado: (2023)

Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma
por: Ponti, Giovanni, et al.
Publicado: (2012)

Acellular dermal matrix for rhinophyma: Is it worth it? A new case report and review of literature
por: Torresetti, Matteo, et al.
Publicado: (2019)

Reconstruction of Full-thickness Soft Tissue Defects with Integra: Risk Factors and Treatment Algorithm
por: Scalise, Alessandro, et al.
Publicado: (2020)

Wound Healing Center: Analysis of preventive measures and new indications in a teaching hospital in central Italy during the Covid‐19 emergency
por: Scalise, Alessandro, et al.
Publicado: (2020)

Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma
por: Satzger, Imke, et al.
Publicado: (2015)

Targeted Therapy for Melanomas Without BRAF V600 Mutations
por: Menzer, Christian, et al.
Publicado: (2022)

Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report
por: Casadevall, David, et al.
Publicado: (2016)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

BRAF Non-V600 Mutations in Metastatic Colorectal Cancer
por: Liu, Junjia, et al.
Publicado: (2023)

Differential Inhibition of Ex-Vivo Tumor Kinase Activity by Vemurafenib in BRAF(V600E) and BRAF Wild-Type Metastatic Malignant Melanoma
por: Tahiri, Andliena, et al.
Publicado: (2013)

Clinical value of early detection of circulating tumour DNA-BRAF(V600mut) in patients with metastatic melanoma treated with a BRAF inhibitor
por: Louveau, Baptiste, et al.
Publicado: (2017)

Methotrexate sensitizes drug-resistant metastatic melanoma cells to BRAF V600E inhibitors dabrafenib and encorafenib
por: Ross, Kayleigh C., et al.
Publicado: (2018)

Immunohistochemistry as an accurate tool for the assessment of BRAF V600E and TP53 mutations in primary and metastatic melanoma
por: Rusu, Stefan, et al.
Publicado: (2021)

Estimated Cost-effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib for Treatment of BRAF V600 Variation Metastatic Melanoma
por: Cai, Chao, et al.
Publicado: (2021)

Amelanotic Melanoma Presenting with Plasmacytoid Morphology and BRAF V600 Mutation
por: Kocovski, Linda, et al.
Publicado: (2015)

BRAF V600 mutations and pathological features in Japanese melanoma patients
por: Yamazaki, Naoya, et al.
Publicado: (2015)

Multifocal BRAF(V600E)-Mutated Melanoma in situ on the Foot
por: Iwama, Eimei, et al.
Publicado: (2015)

Primary Dermal Melanoma: A Rare Clinicopathological Variant Mimicking Metastatic Melanoma
por: Simonetti, Oriana, et al.
Publicado: (2021)

BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2021)

Targeted Therapies Compared to Dacarbazine for Treatment of BRAF(V600E) Metastatic Melanoma: A Cost-Effectiveness Analysis
por: Shih, Vanessa, et al.
Publicado: (2015)

Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice
por: Augustyn, Kourtney, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_749lpv8qbhmu4nh189gccvaolj